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Abstract
Background: The nosocomial infections surveillance system must be strongly effective especially
in highly critic areas, such as Intensive Care Units (ICU). These areas are frequently an
epidemiological epicentre for transmission of multi-resistant pathogens, like Acinetobacter
baumannii. As an epidemic outbreak occurs it is very important to confirm or exclude the genetic
relationship among the isolates in a short time. There are several molecular typing systems used
with this aim. The Repetitive sequence-based PCR (REP-PCR) has been recognized as an effective
method and it was recently adapted to an automated format known as the DiversiLab system.
Methods: In the present study we have evaluated the combination of a newly introduced software
package for the control of hospital infection (VIGI@ct) with the DiversiLab system. In order to
evaluate the reliability of the DiversiLab its results were also compared with those obtained using
f-AFLP.
Results: The combination of VIGI@ct and DiversiLab enabled an earlier identification of an A.
baumannii  epidemic cluster, through the confirmation of the genetic relationship among the
isolates. This cluster regards 56 multi-drug-resistant A. baumannii isolates from several specimens
collected from 13 different patients admitted to the ICU in a ten month period. The A. baumannii
isolates were clonally related being their similarity included between 97 and 100%. The results of
the DiversiLab were confirmed by f-AFLP analysis.
Conclusion:  The early identification of the outbreak has led to the prompt application of
operative procedures and precautions to avoid the spread of pathogen. To date, 6 months after
the last A. baumannii isolate, no other related case has been identified.
Published: 8 June 2008
BMC Infectious Diseases 2008, 8:79 doi:10.1186/1471-2334-8-79
Received: 3 September 2007
Accepted: 8 June 2008
This article is available from: http://www.biomedcentral.com/1471-2334/8/79
© 2008 Fontana et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2008, 8:79 http://www.biomedcentral.com/1471-2334/8/79
Page 2 of 9
(page number not for citation purposes)
Background
Interest in Acinetobacter baumannii continues to rise. One
of the main reasons is the emergence of multi-resistant
strains, which cause sudden outbreaks of infection involv-
ing several patients in a ward and/or in different areas of
the hospital [1,2]. In clinical practice, Acinetobacter infec-
tions are influenced by various risk-factors: the use of
medical devices (such as: endotracheal tubes, intravascu-
lar and urinary catheters), the exposure to broad-spectrum
antibiotics and the type of ward where a patient is admit-
ted (e.g. in ICUs the infection rate is often high) [3,4]. The
sum of these factors contributes to sudden outbreaks that
are difficult to control and prevent. Another worrisome
aspect of A. baumannii infections is that the patients with
symptoms are likely to represent the tip of the coloniza-
tion iceberg, because significant unobserved dissemina-
tion also occurs [1]. Ideally, the diagnostic laboratory
should be involved in active as well as in passive (or lab-
oratory-based) surveillance, and in the subsequent molec-
ular typing of microbial pathogens involved in an
epidemic cluster [5-7]. Microbial typing methods have
become an integral part of clinical laboratories. Many
microbial typing methods are available: PCR multilocus
enzyme electrophoresis (MLEE), moltilocus sequence typ-
ing (MLST), pulsed-field gel electrophoresis (PFGE),
restriction fragment length polymorphisms (RFLP), DNA
sequencing, ribotyping, restriction fragment length poly-
morphism studies, randomly amplified polymorphism
DNA (RAPD), amplified fragment length polymorphism
(AFLP) and repetitive sequence-based PCR (REP-PCR) [8].
The choice of the proper typing method is not easy and
limitations are described for each: MLEE is useful only to
provide the overall genetic relatedness and diversity; AFLP
yield complex DNA profile that can be challenging to
interpret; RAPD has poor inter- and intra-laboratory
reproducibility; MLST are labour intensive and costly;
PFGE has difficulty in resolving bands of similar size.
Essentially very few typing methods assess outbreaks in
real time, provide comprehensive surveillance and epide-
miological data, and have data-archiving capability to
build libraries. The REP-PCR method uses primers that
target non-coding repetitive sequences interspersed
throughout the bacterial DNA and is an established
approach for subspecies classification. It was recently
commercially adapted to an automated format the Diver-
siLab, which allows simplistic data elaboration, archiving,
retrieval and reporting [8]. In the present paper we show
the results of our experience, in studying an A. bauamannii
outbreak, based on the combined use of a laboratory-
based surveillance system (the VIGI@ct) and a new
molecular typing system: the DiversiLab. In order to vali-
date the system the results of the DiversiLab were com-
pared with those obtained by using f-AFLP assay.
Methods
Laboratory-based surveillance system
The Microbiology laboratory of "Tor Vergata" Teaching
Hospital uses a surveillance system named VIGI@ct®, ver-
sion 1.2 (bioMèrieux; Las Balmas, France). The system
allows the monitoring of pathogen circulation either
those with multi-resistant phenotypes (Multi Drug Resist-
ant) or those defined as alert organisms in sensu lato. In
our recent publication we have already extensively
described how efficiently the system can be used to con-
trol, in real time, the hospital infection as well as the dif-
fusion of pathogens [9]. The VIGI@ct is designed to work
with Windows NT and is connected to the Laboratory
Information System (LIS; Dasilab-Delphi; Dasit) so that
the VIGI@ct receives all the analysis requested from the
clinicians in the wards and collects them in the LIS. This
connection is also used to acquire additional patient
information such as admission and discharge dates or
internal location changes, as well as demographic data
supplied by the LIS. The LIS is also linked with the auto-
mated system VITEK 2 (bioMérieux) used in our labora-
tory to perform microbial identification as well as the
antimicrobial susceptibility testing of the isolates. Every
day the microbiologists launch the data integration from
the LIS and VIGI@ct using two program functions: 'receiv-
ing the requests' and 'receiving the results' from the LIS. In
this manner, the VIGI@ct receives all the bacteriological
data coming from the LIS connection which are concen-
trated in the general bacteriology database of the
VIGI@ct, according to the user-defined criteria, where
they can be viewed or used at any time for epidemiologi-
cal studies. This type of connection allows the VIGI@ct
real time identification of all pathogens responsible for
hospital acquired infections (HAIs) using selection crite-
ria established by the user and monitored continuously by
the program. To define an HAIs the CDC criteria are used.
Patients
The thirteen patients (nine males and four females) had a
median age of 59; Seven patients displayed a simple colo-
nization (based on clinical evidence), while the remain-
ing six developed infection (Table 1).
A. baumannii clinical isolates
From October 2005 to August 2006, 56 isolates of A. bau-
mannii (41 isolated in infected patients and 15 in colo-
nized patients), from 13 patients admitted to the medical
ICU, were evidenced by the VIGI@ct®. Table 1 lists the
sample data collected from each patient. All A. baumannii
isolates were biochemically characterized and studied for
their antimicrobial susceptibilities using VITEK 2
(bioMérieux). After isolation the strains were stored at -
70°C in 0.5 ml of defibrinated bovine blood for further
investigation.BMC Infectious Diseases 2008, 8:79 http://www.biomedcentral.com/1471-2334/8/79
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Clones
Clones are identified by very high levels of similarity. The
latter is calculated using DiversiLab system by Pearson
correlation coefficient or by Dice coefficient for f-AFLP [8-
10].
Environmental screening
The Hospital Infection Control team of our hospital (HIC;
composed of a microbiologist, a hygienist, a chemist, an
expert in infectious disease and several hospital manag-
ers) decided to monitor the presence of the micro-organ-
ism in the ICU environment. Environmental sampling
was carried out in the ICU at the end of July. A total of 168
sites were sampled from the patients' immediate environ-
ment. These included patients' monitors, bed frames, X-
ray illuminator, echograph, equipment trolley, and any
other surface, including desktops of the clinicians, as well
as walls and floor near the patient's beds. Each site was
catalogued and the same 168 sites were investigated again
after one month (after the intensive cleaning of the ward).
The sites were sampled using sterile swabs moistened with
sterile saline solution and then processed as reported by
Denton et al. [11].
Carbapenem resistance characterization
PCR reaction for detection of the blaIMP and blaVIM genes
was performed according to Docquier et al; the blaOXA-58
was investigated by PCR assays on genomic DNAs using
previously described primers pairs [12,13].
Fingerprinting of the isolates using the DiversiLab system
The isolates were fingerprinted using the REP-PCR auto-
mated in the DiversiLab system (Bacterial Bar Codes, Inc;
now distributed by bioMèrieux), version 3.3. DNA was
extracted from a bacterial suspension in physiologic
saline, with a turbidity 0.5 (Mac Farland scale) using the
UltraClean Microbial DNA Isolation kit (MO BIO Labora-
tories, Inc.) according to the manufacturer's instructions.
After extraction the DNA was electrophoresed in 1.5%
agarose and stained with Sybrsafe (Invitrogen). The fin-
gerprinting of the isolates was performed using Acineto-
bacter  Kit (DiversiLab) following the instructions
contained in "REP-PCR worksheet". At the end of the
amplification reaction, samples were loaded in a chip
(following the loading sequence numbers illustrated in
the chip Worksheet) and run using the Agilent 2100 Bio-
analyzer (Agilent Technologies). When the run was com-
pleted the results were sent via internet to the Bacterial
Barcodes Database and analysed by Bionumerics soft-
ware. Analysis was performed using the DiversiLab soft-
ware with the Pearson correlation coefficient to determine
the distance matrices and the un-weighted-pair group
method with arithmetic mean (UPGMA) to create den-
drograms. Report were automatically generated and
included: dendrogram, electropherograms, virtual gel
images, similarity matrix, scatter plots, and selectable
demographic fields to aid the interpretation of the data
[8,11,12,14].
Fingerprinting of the isolates using f-Amplified Fragment 
Length Polymorphism
The genetic relationship among the isolates was also
determined using the commercial kit f-AFLP Microbial
fingerprinting (Applera; Foster City, California) according
to the manufacturer's instructions. The f-AFLP reactions
were loaded and run on the ABI 310 DNA genetic analyzer
(Applera). Each f-AFLP reaction was analysed using
Genescan software and Genographer program version
1.6.0 (kindly provided by James J. Benham). Cluster anal-
ysis was performed using the UPGMA. The percentage
similarity between patterns was calculated using the Dice
correlation coefficient. The cluster analysis of a single out-
break was completed in a time ranging from 72 h to 96 h
[9].
Table 1: A. baumannii: samples and first collection date by each patient.
Patients First sample collection date Specimen (no. of examined specimens) Infection/colonization Sub clone no.
Patient 1 03-December-2005 CVC (2), Urine (2); ASB (2) Infection 1
Patient 2 18-October-2005 BAL (2), Urine (1), CVC (2), Blood (2) Infection 2
Patient 3 16-December-2005 ASB (2) Colonization 3
Patient 4 21-December-2005 ASB (1), Blood (6), Infection 4
Patient 5 11-January-2006 Urine (1) Colonization 5
Patient 6 05-May-2006 ASB (2) Colonization 6
Patient 7 08-May-2006 Blood (3), ASB (1), Urine (5) Infection 7
Patient 8 18-June-2006 ASB(1), CVC(1), Blood(5) Infection 8
Patient 9 22-June-2006 ASB(3), Blood(2) Infection 9
Patient 10 12-July-2006 Stool(1) Colonization 10
Patient 11 22-July-2006 ASB(3), BAL(1), CVC(2) SW(1) Colonization 11
Patient 12 26-July-2006 Urine(1) Colonization 12
Patient 13 28-July-2006 ASB(1) Colonization 13
ASB: endothracheal aspirates, BAL:bronchoalveoar lavage, CVC: central venous chateter, SW: swab wound.BMC Infectious Diseases 2008, 8:79 http://www.biomedcentral.com/1471-2334/8/79
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Results
Description of the outbreak
From October 2005 to August 2006, 56 clinical isolates of
A. baumannii were evidenced by the VIGI@ct®. The micro-
organism first appeared in October 2005, and from that
time it was responsible of an epidemic cluster consisting
of 56 strains isolated from 13 patients admitted to the
medical ICU. Our medical ICU is a seven-bed unit (five in
an open-plan area and two in single rooms), in which are
admitted 135 patients per year. The frequency of HAI
ranges from 20 to 43%.
The ten most frequent pathogens isolated in the ICU,
from October 2005 and October 2006 were: Pseudomonas
aeruginosa (16%), Klebsiella pneumoniae (15%), Staphyloco-
ccus epidermidis (9%),  Enterococcus faecalis (8%),
Escherichia coli (7%), Staphylococcus aureus (7%), A. bau-
mannii (7%), Candida albicans (7%), Enterococcus faecium
(3%), Staphylococcus haemolyticus (2.5%).
The first patient, in whom A. baumannii was isolated, was
admitted to the ICU coming from another hospital (in
October). This patient, evidently imported the A. bauman-
nii to our ICU ward, where the pathogen was cross-trans-
mitted to other patients. Out of 13 patients, seven
displayed simple colonization (based on clinical evi-
dence) while the others developed infections (Table 1). In
January the outbreak became evident and to reduce infec-
tion rate the environmental cleaning was enhanced and
the hand hygiene procedure was re-enforced (providing
staff with alcohol hand rub). Initially these measures
appeared to be effective, but the pathogen diffusion re-
started on May. In July, in two weeks, the A. baumannii
was isolated in four different patients. The laboratory
promptly documented the epidemic peak and the head of
ICU prepared a detailed report for the Sanitary Direction
(SD) describing the last infection cases. The SD decided to
close the ICU for about one month and existing patients
were moved to the ICUs of adjacent hospitals. The ward
environment was thoroughly cleaned using detergent and
disinfectant and all disposable materials were replaced.
Since the ward was re-opened, A. baumannii has no longer
been isolated.
Clinical isolates
Fifty-six isolates of A. baumannii obtained from 13
patients, were cultured from a variety of sites, including
endothracheal aspirates (ASB), bronchoalveoar lavage
(BAL), central venous device tips (CVC), blood, wound
swab and urine samples (Table 1). Among the 56 isolates
from 13 different patients we identified 13 sub clones. The
results of the REP-PCR analysis (Pearson correlation coef-
ficient) as well as that of f-AFLP (using the Dice's coeffi-
cient) demonstrate, in fact, that each patient was
colonized/infected from a single sub clone (Table 1). To
each sub clone was assigned a number that was the same
used to identify the patient. Figure 1 reports the REP-PCR
profiles of the 13 sub clones and their similarity matrix
The REP-PCR analysis showed a clonal relationship
among the isolates (being their similarity greater than the
97%).
All the clinical isolates had the same antibiograms, being
susceptible to gentamicin and colistin, but resistant to
imipimen, meropenem, 3rd generation cephalosporins,
amikacin, ciprofloxacin, ampicillin, aztreonam, and pip-
eracillin-tazobactam. All strains tested were positive for
the blaOXA-58 gene (data not shown).
Environmental screening
Out of 168 environmental sites investigated, 15 were
found to be contaminated by A. baumannii. Figure 2
shows the similarity matrix and the REP-PCR profiles of
the environmental isolates, which are clonally related, as
their similarity ranged from 97 to 100%. Following clean-
ing and disinfection of the ICU ward, no A. baumannii iso-
lates were grown from repeated environmental cultures.
Relationship among clinical and environmental isolates
As shown in Figure 3, the genetic relationship is consist-
ently high between the 15 environmental isolates (named
sub clones) and the 13 sub clones from patients (the per-
cent of similarity was greater than 97.5%) demonstrating
transmission from patient-to-patient as well as spreading
of the pathogen in the ICU environment.
Comparison of REP-PCR and f-AFLP results
The results of f-AFLP assays (performed on patient – as
well as on environmental-strains; data not shown) com-
pared with those obtained using REP-PCR, showed to be
very similar. Both exhibit high discriminatory power, but
f-AFLP appeared to be more labour intensive than REP-
PCR automated in the DiversiLab system. In fact, the clus-
ter analysis using f-AFLP is completed in a time ranging
from 72 h to 96 h, while the DiversiLab automation
allows a complete microbial typing analysis in approxi-
mately 4 h.
Discussion
The use of a combined method based on a laboratory sur-
veillance system and molecular typing methods helped us
in the rapid detection of pathogen circulation in our hos-
pital [9]. The prompt identification of a pathogen, albeit
not necessarily associated to an infection, is of great
importance in such critical areas, like the ICUs, because
they can lead to the immediate alert programme. The con-
sequent application of precautionary measures can reduceBMC Infectious Diseases 2008, 8:79 http://www.biomedcentral.com/1471-2334/8/79
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Dendrogram and similarity matrix for A. baumannii sub clones from 13 patients Figure 1
Dendrogram and similarity matrix for A. baumannii sub clones from 13 patients. 1–13 = sub clones from 13 
patients. 14 = an unrelated strain of A. baumannii, not from ICU patients.BMC Infectious Diseases 2008, 8:79 http://www.biomedcentral.com/1471-2334/8/79
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REP-PCR profiles and similarity matrix of the environmental sub clones Figure 2
REP-PCR profiles and similarity matrix of the environmental sub clones. 1 = strain cultured from the ventilator of 
bed no.1; 2, 6, 11 = strain cultured from the floor near the patient beds no.1, 3,4 3, 9 = strain cultured from the desk surfaces 
of beds no.4 and 7; 4 = strain cultured from buttons on the ventilator of bed no.3; 5, 12 = strain cultured from ventilator key-
board of bed no.3 and 6; 7 = strain cultured from edge side of bed no.8; 8 = strain cultured from drawers of the bedside table 
near bed no.5; 10 = strain cultured from service desk near bed no.1; 13 = strain cultured from the floor at the entrance of ICU; 
14 = strain cultured from folder of medical record of patient in the bed no.1. 15 = strain cultured from monitor keyboard of 
bed no.3.
 BMC Infectious Diseases 2008, 8:79 http://www.biomedcentral.com/1471-2334/8/79
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the number of infected patients as well as of those colo-
nized [11,15-17]. Close cooperation between clinicians
and microbiologists is also important for resolving an epi-
demic event. Microbiologist plays a primary role in the
study of isolates circulating in the hospital. Accomplish-
ing this control requires adequate systems (hardware and
software) for the real time control of pathogens dissemi-
nation. At the same time, the microbiologist must also be
able to rapidly confirm or exclude the possibility of an
epidemic cluster by performing fingerprinting of the iso-
lates [4-6,9]. Electronic laboratory-based surveillance
methods have already been demonstrated to be more use-
ful than the detection of nosocomial infection by hospi-
tal-wide medical records, since the latter is neither as
sensitive nor always consistently applied [18,19]. Also,
our experience confirms the effectiveness of the use of sur-
veillance software, such as VIGI@ct®, in the rapid and sen-
sitive identification of HAIs. The VIGI@ct® is a new system
introduced for the control of HAIs, which is already used
in several hospitals in Italy but our experience is the first
to be described [9]. The combination of VIGI@ct® and the
DiversiLab system appeared to be strongly efficient for the
early detection of pathogen circulation and in the conse-
quent confirmation/exclusion of genetic relatedness
among the isolates. These tools are particularly useful
when the microbiologist is asked to analyze and compare
Rep-PCR profiles of the environmental – as well as patients' sub clones Figure 3
Rep-PCR profiles of the environmental – as well as patients' sub clones. 1 = patient's sub clone 9; 2 = environmental-
sub clone1; 3 = environmental-sub clone 6; 4 = environmental-sub clone 5; 5 = patient's sub clone 5; 6 = patient's sub clone 6; 
7 = patient's sub clone 7; 8 = patient's sub clone 8; 9 = environmental-sub clone 7; 10 = patient's sub clone 1; 11 = patient's sub 
clone 2; 12 = patient's sub clone 3; 13 = patient's sub clone 4; 14 = patient's sub clone 10; 15 = patient's sub clone 11; 16 = 
environmental-sub clone 9; 17 = environmental-sub clone 8; 18 = environmental-sub clone 10; 19 = environmental-sub clone 
11; 20 = environmental-sub clone 12; 21 = environmental-sub clone 3; 22 = environmental-sub clone 4; 23 = environmental-
sub clone 2; 24 = patient's sub clone 12; 25 = patient's sub clone 13; 26 = environmental-sub clone 13; 27 = environmental-sub 
clone 14; 28 = environmental-sub clone 15.BMC Infectious Diseases 2008, 8:79 http://www.biomedcentral.com/1471-2334/8/79
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a large number of isolates (from patients as well as the
hospital environment) and needs a simple system to com-
pare the genetic profiles of numerous isolates in a reason-
able time. Our environmental investigation, revealing a
consistent contamination, led to the closure of the ICU
and to its decontamination by disinfection. The Sanitary
Direction authorized the readmission of the patients in
the ward only after a second environmental control
revealed the eradication of the pathogen. The high cost of
one month of ICU closure had a heavy consequence on
the behaviour of the ICU staff, which was more careful in
the application of prevention measures and protocols. To
date no A. baumannii has been isolated from the environ-
ment, and although one recent patient admitted in the
ICU was determined to be colonized by this pathogen, it
remains a single isolate from a single patient, and no
spread of the pathogen has occurred.
Conclusion
The combination of REP-PCR and relative analysis of data
in the DiversiLab seems to be an excellent choice. In our
previous work we described the use of f-AFLP for the fin-
gerprinting of the isolates, but although this technique
appears to be good, particularly for its discriminatory
power, it remains defective because of inadequate support
from software that is unable to compare the fingerprinting
of numerous isolates at the same time (it needs the use of
an additional software). On the contrary the DiversiLab
system has been proved to be easy to use. Our findings
show that the DiversiLab results are reliable (fingerprint-
ing analysis of the isolates obtained using the DiversiLab
are similar to those obtained using f-AFLP). The system
exhibits high levels of reproducibility, offers standardized
kits and it is cost effective (the costs of the system has been
already demonstrated to be favourable especially when
compared to other methods, including f-AFLP) [8]. More-
over, the high level of automation of the system satisfies
the needs of the laboratory desiring a more convenient,
user-friendly surveillance system. The short time with
which the microbiologist identifies a possible epidemic
cluster and then confirms the genetic relationship among
the isolates is extremely important because it allows the
HIC of the hospital to promptly implement measures to
stop the spread of a pathogen.
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